Top RSI Trades for the day: BIOLASE, Inc. (NASDAQ:BIOL)

BIOLASE, Inc. (NASDAQ:BIOL) with the stream of -1.44% in the last hour of trading session.

BIOLASE, Inc. (BIOL) shares fell -1.44% to close at $1.02. About 90,922,336 million shares traded hands on 17.24M trades for the day, compared with an average daily volume of 17.24M shares out of a total float of 84.36M. After opening the trading day at $1.26, shares of BIOLASE, Inc. stayed within a range of $0.88 to $1.38.

With today’s loss, BIOLASE, Inc. now has a market cap of $88.94M. Shares of BIOLASE, Inc. have been trading within a range of $0.21 and $1.38 over the last year, and it had a 50-day SMA of $194.03% and a 200-day SMA of $165.71%.

BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode laser systems to perform soft tissue, hygiene, cosmetic procedures, and teeth whitening, as well as to provide temporary pain relief; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces, and teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Irvine, California.

The PEG ratio is used to determine a stock’s value while taking the company’s earnings growth into account, and is considered to provide a more complete picture than the P/E ratio. Last traded has a PEG ratio of 0 where as its P/E ratio was 0. The overall volume in the last trading session was 90,922,336 shares.

Important Results:

BIOLASE, Inc. has P/S value of 3.65 while its P/B esteem remains at 6.12. Likewise, the company has Return on Assets of -108.10%, Return on Equity of 0 and Return on Investment of -112.90%. The company demonstrates Gross Margin and Operating Margin of 36.80% and -75.20% respectively.

BIOL’s price to sales ratio for trailing twelve months was 3.65 and price to book ratio for most recent quarter was 6.12, whereas price to cash per share for the most recent quarter was 4.73. The Company’s price to free cash flow for trailing twelve months was recorded as 0.

Historical Performances to Consider:

The Stock’s performances for Monthly, weekly, half-yearly, quarterly & year-to-date are mentioned below:-

On a Monthly basis the stock was 247.48%. On a weekly basis, the stock remained 101.94%. The half-yearly performance for the stock has 122.22%, while the quarterly performance was 243.69%. Looking further out we can see that the stock has moved 149.58% over the year to date. Other technical indicators are worth considering in assessing the prospects for EQT. RSI for instance was stand at 83.52.

Jake Charles

About Jake Charles

This is Jake Charles, a Senior News Writer for “Stocks Equity”. I covers “Active Stocks” sector and writes about trending Active Hot companies from an exclusive and “out of the box” perspective. I worked independently as a self motivator and with the financial institute as financial adviser to invest in the Active sector for over 9 years in the developing countries by introducing new phases and ways to improve in this sector. I like to travel all over the globe to get new experience and provide by best services to the companies. As an advisor I like to work with new people to share and explore new ideas keeping in view minimizing the operating cost and giving the best final product through new technology and minimizing the time of development.

View all posts by Jake Charles →

Leave a Reply

Your email address will not be published. Required fields are marked *